Innovative Therapies in Europe

DIA-EUCOPE Workshop: 5 Years of ATMPs on the Market - Lessons Learned

Back to Agenda

Session 5: Emerging EU HTA - Will Joint Scientific Consultations and Joint Clinical Assessments on the European level enable faster and broader patient access to ATMPs?

Global Access Senior Health Systems Strategy Leader HTA & Reimbursement

F. Hoffmann-La Roche, Switzerland

Topics covered in this session include:

What is the EC’s vision for accelerated patient access in Europe by moving to a European HTA approach?
How a flexible yet predictable should HTA approach for ATMPs look like?
Will JSC help early alignment for non-traditional evidence requirements and needs?
Which role will RWE & Registries play along the product life cycle to close data gaps?

European Medicines Agency, Netherlands

Scientific Senior Specialist (Risk Management)

Marcus Guardian

EUnetHTA, Netherlands

COO EUnetHTA 21, General Manager - Heads of HTA Agencies Group

Maria João Garcia, PharmD

F. Hoffmann-La Roche, Ltd., Switzerland

Global Access Evidence Lead

Have an account?